Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Bio Medica Laboratories
Price Band
₹132.0–139.0
Issue Size
₹52.43 Cr
Lot Size
1,000 shares
Min Investment
₹278,000
GMP
₹-9.0 (-6.47%)
Issue Price
₹139.0
calendar_month Important Dates
bar_chart Subscription Status
Subscription data unavailable
trending_up Grey Market Premium (GMP)
GMP
₹-9.0
GMP %
-6.47%
Est. Listing
₹130.0
schedule Updated: 14 Jul 2026 15:51
Share GMP:
business About the Company
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on liquid and dry powder injectables for both human and veterinary healthcare applications. The company produces a broad range of ethical medicines, generic formulations, and over-the-counter (OTC) pharmaceutical products. Its injectable products are manufactured in both single-dose and multi-dose formats to cater to diverse therapeutic and clinical requirements. Product portfolio: Liquid Injectables – 58 products Dry Powder Injectables – 15 products The company offers a diversified pharmaceutical portfolio comprising generic medicines, branded formulations, OTC products, and other injectable medications across multiple therapeutic categories. Bio Medica Laboratories primarily operates under a B2B contract manufacturing model, developing and manufacturing formulations for pharmaceutical companies based on their specific product requirements and technical specifications. The company holds certifications for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), issued by the Food & Drugs Administration, Madhya Pradesh, reflecting its focus on quality and regulatory compliance. It operates through two manufacturing facilities located in Indore, Madhya Pradesh. Competitive strengths: Multi-product manufacturing capabilities with a diversified injectable portfolio. Experienced promoters, management team, and skilled workforce. Strong quality assurance processes supported by regulatory certifications. Established long-term relationships with customers in the pharmaceutical industry.
payments Company Financials (₹ Cr)
As of 2025-11-30
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Key Ratios
EPS
₹10.67
NAV
₹16.05
ROE
99.59%
ROCE
48.20%
RoNW
99.59%
P/B Value
8.66
P/E Ratio
13.03
Market Cap
₹174.79 Cr
PAT Margin
25.64%
Debt/Equity
1.02
Promoters
Mukesh Mehta and Pradeep Mehta
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Repayment of loan 6.50 2 Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises 28.50 3 General Corporate Purposes 7.05 4 Issue Expense 5.14 Total 47.19
info Issue Details
pie_chart Investor Allocation
Registrar
Lead Managers / Book Running
timeline IPO Timeline
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026